Association of baloxavir treatment timing with serial interval and household transmission of influenza through a likelihood-based analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Timing on Baloxavir Treatment Regarding Serial Interval and Influenza Transmission in Households: A Likelihood-Based Study

  • By

  • Jihyeon Kim

  • Minju Ryu

  • Hiroshi Nishiura

  • Hyojung Lee

  • September 21, 2026

Share

  • 1

    Baloxavir marboxil was approved by the US FDA in 2018 and acts through a mechanism distinct from neuraminidase inhibitors.

  • 2

    Prior studies have associated baloxavir treatment with lower household secondary attack rates, particularly when given early after symptom onset.

  • 3

    In this study, the serial interval was the time between symptom onset in an index case and the earliest secondary case in the household.

  • 4

    The study modeled how baloxavir treatment timing related to the serial interval and estimated household secondary attack rates.

  • 5

    Data came from an internet-based survey of Japanese households with at least one symptomatic influenza case from October 2018 through February 2019.

Original Source(s)

Association of baloxavir treatment timing with serial interval and household transmission of influenza through a likelihood-based analysis

  • by Jihyeon Kim, Minju Ryu, Hiroshi Nishiura, Hyojung Lee

  • September 21, 2026

Related Content

Accountable Action End Points for Evaluating Artificial Intelligence in Digital Public Health

Nirsevimab may curb RSV severity

Real-world estimates showed protection across emergency, inpatient, and intensive care settings during Canada’s first universal immunization season.

How HCPs can help students stay healthy at school

"We are at risk as a nation of losing our measles elimination status."